Suppr超能文献

耐碳青霉烯类药物的两次暴发所面临的挑战:从头孢地尔敏感性试验到头孢地尔耐药突变体的出现

Challenges Facing Two Outbreaks of Carbapenem-Resistant : From Cefiderocol Susceptibility Testing to the Emergence of Cefiderocol-Resistant Mutants.

作者信息

Rodríguez-Aguirregabiria Montserrat, Lázaro-Perona Fernando, Cacho-Calvo Juana Begoña, Arellano-Serrano Mª Soledad, Ramos-Ramos Juan Carlos, Rubio-Mora Eduardo, Díaz-Almirón Mariana, Asensio-Martín Mª José

机构信息

Critical Care Department, Hospital Universitario La Paz, IdiPAZ, 28046 Madrid, Spain.

Microbiology Department, Hospital Universitario La Paz, 28046 Madrid, Spain.

出版信息

Antibiotics (Basel). 2024 Aug 21;13(8):784. doi: 10.3390/antibiotics13080784.

Abstract

Carbapenem-resistant (CRAB) infections are associated with poor outcomes depending on patient's conditions, clinical severity and type of infection, and treatment is challenging given the limited therapeutic options available. The aim of this study was to describe the clinical and microbiological characteristics of two outbreaks caused by CRAB in an intensive care unit (ICU). In addition, the mechanisms of resistance detected in these strains and the treatment chosen according to the available therapeutic options were analyzed. Overall, 28 patients were included. Ten patients (35.71%) had ventilator-associated pneumonia (VAP), ten (35.71%) had a bloodstream infection (BSI), and eight (28.57%) were only colonized. Recurrent infection occurred in 25% (5/20) of infected patients. Two different strains of were isolated from the index patient of the first outbreak. The first strain belonged to the ST85 and carried the carbapenemase gene, while the second belonged to the ST2 and carried and carbapenemase genes. The phylogenetic analysis revealed that the ST2 strain was the cause of the major outbreak, and mutations in the AmpC gene were related to progressive increasing minimum inhibitory concentration (MIC) and finally, cefiderocol-resistance in one strain. The CRAB isolates from the second outbreak were also identified as ST2. Cefiderocol-resistant strains tests identified by the disc diffusion method were involved in 24% (6/25) of nosocomial infections. Using broth microdilution (BMD) ComASP only, 33.3% (2/6) of these strains were cefiderocol-resistant. All-cause ICU mortality was 21.4%. Conclusions: Cefiderocol is the first approved siderophore cephalosporin for the treatment of CRAB infections. Cefiderocol-resistant strains were related with carbapenemase and mutations in the AmpC gene. Cefiderocol-resistant strains or that cannot be properly interpreted by disk diffusion, should be retested using BMD for definitive categorization.

摘要

耐碳青霉烯类鲍曼不动杆菌(CRAB)感染的预后因患者状况、临床严重程度和感染类型而异,且由于可用治疗选择有限,治疗具有挑战性。本研究的目的是描述重症监护病房(ICU)中由CRAB引起的两次暴发的临床和微生物学特征。此外,还分析了在这些菌株中检测到的耐药机制以及根据可用治疗选择所选用的治疗方法。总共纳入了28例患者。10例患者(35.71%)发生呼吸机相关性肺炎(VAP),10例(35.71%)发生血流感染(BSI),8例(28.57%)仅为定植。25%(5/20)的感染患者发生了反复感染。从首次暴发的索引患者中分离出两种不同菌株。第一种菌株属于ST85,携带碳青霉烯酶基因,而第二种属于ST2,携带 和 碳青霉烯酶基因。系统发育分析表明,ST2菌株是主要暴发的原因,AmpC基因的突变与最低抑菌浓度(MIC)的逐步升高有关,最终导致一株菌株对头孢地尔耐药。第二次暴发的CRAB分离株也被鉴定为ST2。通过纸片扩散法鉴定的对头孢地尔耐药的菌株涉及24%(6/25)的医院感染。仅使用肉汤微量稀释法(BMD)ComASP检测时,这些菌株中有33.3%(2/6)对头孢地尔耐药。ICU全因死亡率为21.4%。结论:头孢地尔是首个被批准用于治疗CRAB感染的铁载体头孢菌素。对头孢地尔耐药的菌株与碳青霉烯酶和AmpC基因的突变有关。对头孢地尔耐药或不能通过纸片扩散法正确解读的菌株,应使用BMD重新检测以进行明确分类。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b383/11350900/3078dfe3fcf1/antibiotics-13-00784-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验